A novel drug treatment strategy to fighting resistant cancer

Scientists from FMP, MDC and Charité have discovered new selective and potent active site SHP2 inhibitors, which are able to suppress cancer related metastasis and resistance formation in advanced cellular models.

The results, published in the Journal of Medicinal Chemistry, provide a potential new axis for the treatment of drug-resistant cancers with diminished ERK-signaling.

Original Publication: https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01265